Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet P Hapgood

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Steroids|March 10, 2022
Differential off-target glucocorticoid activity of progestins used in endocrine therapyMaleshigo Komane, Chanel Avenant, Renate Louw-du Toit, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|October 27, 2022
Increased HIV-1 infection in PBMCs treated in vitro with menstrual cycle phase hormones or medroxyprogesterone acetate likely occurs via different mechanismsAlexis J Bick, Chanel Avenant, Michele Tomasicchio, et al.
Pharmacology & Therapeutics|December 14, 2020
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraceptionAlexis J Bick, Renate Louw-du Toit, Salndave B Skosana, et al.
Biochemical and Biophysical Research Communications|October 3, 2020
Characterisation of progestins used in hormonal contraception and progesterone via the progesterone receptorKim Enfield, Meghan Cartwright, Renate Louw-du Toit, et al.
Molecular and Cellular Endocrinology|November 15, 2008
Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interactionKatharina Ronacher, Katie Hadley, Chanel Avenant, et al.
Plos One|May 21, 2014
The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptorYashini Govender, Chanel Avenant, Nicolette J D Verhoog, et al.
Contraception|June 24, 2019
Corrigendum to "Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women" [Contraception 99 (2019) 199-204]Renee Heffron, Sharon L Achilles, Laneta J Dorflinger, et al.
Contraception|December 22, 2018
Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in womenRenee Heffron, Sharon L Achilles, Laneta J Dorflinger, et al.
Scientific Reports|March 15, 2019
The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrationsRoslyn M Ray, Michelle F Maritz, Chanel Avenant, et al.
Plos One|April 27, 2018
Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levelsMichelle F Maritz, Roslyn M Ray, Alexis J Bick, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Steroids|March 10, 2022
Differential off-target glucocorticoid activity of progestins used in endocrine therapyMaleshigo Komane, Chanel Avenant, Renate Louw-du Toit, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|October 27, 2022
Increased HIV-1 infection in PBMCs treated in vitro with menstrual cycle phase hormones or medroxyprogesterone acetate likely occurs via different mechanismsAlexis J Bick, Chanel Avenant, Michele Tomasicchio, et al.
Pharmacology & Therapeutics|December 14, 2020
Pharmacokinetics, metabolism and serum concentrations of progestins used in contraceptionAlexis J Bick, Renate Louw-du Toit, Salndave B Skosana, et al.
Biochemical and Biophysical Research Communications|October 3, 2020
Characterisation of progestins used in hormonal contraception and progesterone via the progesterone receptorKim Enfield, Meghan Cartwright, Renate Louw-du Toit, et al.
Molecular and Cellular Endocrinology|November 15, 2008
Ligand-selective transactivation and transrepression via the glucocorticoid receptor: role of cofactor interactionKatharina Ronacher, Katie Hadley, Chanel Avenant, et al.
Plos One|May 21, 2014
The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptorYashini Govender, Chanel Avenant, Nicolette J D Verhoog, et al.
Contraception|June 24, 2019
Corrigendum to "Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in women" [Contraception 99 (2019) 199-204]Renee Heffron, Sharon L Achilles, Laneta J Dorflinger, et al.
Contraception|December 22, 2018
Pharmacokinetic, biologic and epidemiologic differences in MPA- and NET-based progestin-only injectable contraceptives relative to the potential impact on HIV acquisition in womenRenee Heffron, Sharon L Achilles, Laneta J Dorflinger, et al.
Scientific Reports|March 15, 2019
The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrationsRoslyn M Ray, Michelle F Maritz, Chanel Avenant, et al.
Plos One|April 27, 2018
Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levelsMichelle F Maritz, Roslyn M Ray, Alexis J Bick, et al.
Pageof 5